An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer’s disease

An exploratory, open-label, randomized, multicenter trial of hachimijiogan for mild Alzheimer’s disease

Background: Alzheimer’s disease (AD) is a progressive neurodegeneration and is the most prevalent form of dementia. Intervention at an early stage is imperative. Although three acetylcholinesterase inhibitors (AChEIs) are currently approved for the treatment of mild AD, they are not sufficiently eff...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों: Mosaburo Kainuma, Shinji Ouma, Shinobu Kawakatsu, Osamu Iritani, Ken-Ichiro Yamashita, Tomoyuki Ohara, Shigeki Hirano, Shiro Suda, Tadanori Hamano, Sotaro Hieda, Masaaki Yasui, Aoi Yoshiiwa, Seiji Shiota, Masaya Hironishi, Kenji Wada-Isoe, Daiki Sasabayashi, Sho Yamasaki, Masayuki Murata, Kouta Funakoshi, Kouji Hayashi, Norimichi Shirafuji, Hirohito Sasaki, Yoshinori Kajimoto, Yukiko Mori, Michio Suzuki, Hidefumi Ito, Kenjiro Ono, Yoshio Tsuboi
स्वरूप: लेख
भाषा:English
प्रकाशित: Frontiers Media S.A. 2022-10-01
श्रृंखला:Frontiers in Pharmacology
विषय:
Alzheimer’s disease
hachimijiogan
ADAS‐Jcog
Kampo medicine
cognitive dysfunction
ऑनलाइन पहुंच:https://www.frontiersin.org/articles/10.3389/fphar.2022.991982/full

इंटरनेट

https://www.frontiersin.org/articles/10.3389/fphar.2022.991982/full

समान संसाधन